Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress and VEGF Interference in Ocular Cells.

Dörschmann P, Bittkau KS, Neupane S, Roider J, Alban S, Klettner A.

Mar Drugs. 2019 Apr 30;17(5). pii: E258. doi: 10.3390/md17050258.

2.

Gradual degradation of fucoidan from Fucus vesiculosus and its effect on structure, antioxidant and antiproliferative activities.

Lahrsen E, Liewert I, Alban S.

Carbohydr Polym. 2018 Jul 15;192:208-216. doi: 10.1016/j.carbpol.2018.03.056. Epub 2018 Mar 19.

PMID:
29691015
3.

Size-dependent pharmacological activities of differently degraded fucoidan fractions from Fucus vesiculosus.

Lahrsen E, Schoenfeld AK, Alban S.

Carbohydr Polym. 2018 Jun 1;189:162-168. doi: 10.1016/j.carbpol.2018.02.035. Epub 2018 Feb 12.

PMID:
29580394
4.

Size and molecular weight determination of polysaccharides by means of nano electrospray gas-phase electrophoretic mobility molecular analysis (nES GEMMA).

Weiss VU, Golesne M, Friedbacher G, Alban S, Szymanski WW, Marchetti-Deschmann M, Allmaier G.

Electrophoresis. 2018 May;39(9-10):1142-1150. doi: 10.1002/elps.201700382. Epub 2018 Mar 25. Erratum in: Electrophoresis. 2019 May;40(10):1510.

5.

Effects of fucoidans and heparin on reactions of neutrophils induced by IL-8 and C5a.

Liewert I, Ehrig K, Alban S.

Carbohydr Polym. 2017 Jun 1;165:462-469. doi: 10.1016/j.carbpol.2017.02.051. Epub 2017 Feb 20.

PMID:
28363573
6.

Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.

Eller T, Flieder T, Fox V, Gripp T, Dittrich M, Kuhn J, Alban S, Knabbe C, Birschmann I.

Eur J Cardiothorac Surg. 2017 Apr 1;51(4):624-632. doi: 10.1093/ejcts/ezw368.

PMID:
28043992
7.

Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships.

Schoenfeld AK, Lahrsen E, Alban S.

PLoS One. 2016 Oct 26;11(10):e0165493. doi: 10.1371/journal.pone.0165493. eCollection 2016.

8.

[Oral anticoagulants 2.0].

Alban S.

Med Monatsschr Pharm. 2015 Oct;38(10):371. German. No abstract available.

PMID:
26731854
9.

Interference with the CXCL12/CXCR4 axis as potential antitumor strategy: superiority of a sulfated galactofucan from the brown alga Saccharina latissima and fucoidan over heparins.

Schneider T, Ehrig K, Liewert I, Alban S.

Glycobiology. 2015 Aug;25(8):812-24. doi: 10.1093/glycob/cwv022. Epub 2015 Apr 15.

PMID:
25878069
10.
12.

Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.

Schoenfeld AK, Vierfuß S, Lühn S, Alban S.

J Pharm Biomed Anal. 2014 Jul;95:130-8. doi: 10.1016/j.jpba.2014.02.021. Epub 2014 Mar 7.

PMID:
24667567
13.

Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.

Eller T, Busse J, Dittrich M, Flieder T, Alban S, Knabbe C, Birschmann I.

Clin Chem Lab Med. 2014 Jun;52(6):835-44. doi: 10.1515/cclm-2013-0936.

PMID:
24406289
14.

Development of both colorimetric and fluorescence heparinase activity assays using fondaparinux as substrate.

Schiemann S, Lühn S, Alban S.

Anal Biochem. 2012 Aug 1;427(1):82-90. doi: 10.1016/j.ab.2012.04.032. Epub 2012 May 9.

PMID:
22579846
15.

Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.

Alban S, Lühn S, Schiemann S.

Anal Bioanal Chem. 2011 Jan;399(2):681-90. doi: 10.1007/s00216-010-4252-0. Epub 2010 Oct 16.

PMID:
20953779
16.

Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples.

Alban S, Lühn S, Schiemann S, Beyer T, Norwig J, Schilling C, Rädler O, Wolf B, Matz M, Baumann K, Holzgrabe U.

Anal Bioanal Chem. 2011 Jan;399(2):605-20. doi: 10.1007/s00216-010-4169-7. Epub 2010 Sep 8. Erratum in: Anal Bioanal Chem. 2011 Jan;399(3):1395.

PMID:
20824424
17.

Simple fluorescence assay for quantification of OSCS in heparin.

Lühn S, Schiemann S, Alban S.

Anal Bioanal Chem. 2011 Jan;399(2):673-80. doi: 10.1007/s00216-010-3867-5. Epub 2010 Jun 16. Erratum in: Anal Bioanal Chem. 2011 Jan;399(3):1395.

PMID:
20552175
18.

Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.

Beyer T, Matz M, Brinz D, Rädler O, Wolf B, Norwig J, Baumann K, Alban S, Holzgrabe U.

Eur J Pharm Sci. 2010 Jul 11;40(4):297-304. doi: 10.1016/j.ejps.2010.04.002. Epub 2010 Apr 23.

PMID:
20399266
19.

Development and evaluation of a fluorescence microplate assay for quantification of heparins and other sulfated carbohydrates.

Lühn S, Schrader T, Sun W, Alban S.

J Pharm Biomed Anal. 2010 May 1;52(1):1-8. doi: 10.1016/j.jpba.2009.12.014. Epub 2009 Dec 23.

PMID:
20071127

Supplemental Content

Loading ...
Support Center